We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

17 hedge funds and large institutions have $5.57M invested in Benitec Biopharma in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

128% more capital invested

Capital invested by funds: $2.44M → $5.57M (+$3.13M)

0.12% less ownership

Funds ownership: 2.45% → 2.32% (-0.12%)

19% less funds holding

Funds holding: 21 → 17 (-4)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
17
Holders Change
-4
Holders Change %
-19.05%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$709
2
Wells Fargo
Wells Fargo
California
+$4

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$47K
2
Walleye Capital
Walleye Capital
New York
-$45.3K
3
VF
Virtu Financial
New York
-$15.4K
4
Two Sigma Investments
Two Sigma Investments
New York
-$5.61K
5
CF
Cantor Fitzgerald
New York
-$5.26K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Suvretta Capital Management
New York
$3.12M – – –
Franklin Resources
2
Franklin Resources
California
$2.38M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$17.8K – – –
VF
4
Virtu Financial
New York
$13K -$15.4K -4,038 -56%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$11.5K – – –
Morgan Stanley
6
Morgan Stanley
New York
$9.21K -$1.54K -405 -15%
State Street
7
State Street
Massachusetts
$5.11K – – –
PAG
8
Private Advisor Group
New Jersey
$3.14K – – –
WA
9
WealthTrust Axiom
Pennsylvania
$3.09K – – –
Northern Trust
10
Northern Trust
Illinois
$2.82K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$1.78K -$23 -6 -1%
RhumbLine Advisers
12
RhumbLine Advisers
Massachusetts
$752 +$709 +186 New
Group One Trading
13
Group One Trading
Illinois
$358 – – –
MHR
14
Matthew Hamilton Rosenberg
$91 – – –
UBS Group
15
UBS Group
Switzerland
$82 – – –
Wells Fargo
16
Wells Fargo
California
$48 +$4 +1 +9%
Renaissance Technologies
17
Renaissance Technologies
New York
– -$47K -13,228 Closed
Walleye Capital
18
Walleye Capital
New York
– -$45.3K -12,705 Closed
Two Sigma Investments
19
Two Sigma Investments
New York
– -$5.61K -1,573 Closed
CF
20
Cantor Fitzgerald
New York
– -$5.26K -1,474 Closed
CAN
21
Cetera Advisor Networks
California
– -$2.59K -727 Closed

BNTC Hedge Fund Activity: Q2 2023 in Review

17 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2023, worth a combined $5.57M — up 128% from $2.44M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BNTC and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $709. The largest seller was Renaissance Technologies, exiting entirely with an estimated $47K sold.

  • 17 institutional investors held Benitec Biopharma (BNTC) as of Q2 2023, down from 21 in Q1 2023.
  • Funds reported $5.57M of Benitec Biopharma stock for Q2 2023, up 128% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q2 2023 and 5 closed out, a net change of -4 holders.
  • The largest Benitec Biopharma buyer in Q2 2023 was RhumbLine Advisers, an estimated $709 added.
  • The largest Benitec Biopharma seller in Q2 2023 was Renaissance Technologies, an estimated $47K sold.

Based on aggregated 13F filings for Q2 2023.